1. if female, pregnant, breastfeeding, or planning a pregnancy during the study. 2. severe or critical covid-19: 1. severe covid-19: respiratory frequency \>30 breaths per minute, spo2 \<94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) \<300 mmhg, or lung infiltrates \>50%. 2. critical covid-19: respiratory failure, septic shock, and/or multiple organ dysfunction. 3. current hospital admission for any cause. 4. history of previous confirmed sars-cov-2 infection. 5. history of significantly abnormal liver function (child pugh c). 6. history of chronic kidney disease (ckd) ≥ stage 4, or need of dialysis treatment. 7. any pre-existing condition that increases risk of thrombosis. 8. history of allergic reactions to blood or plasma products or methylene blue. 9. known iga deficiency with anti-iga antibodies. 10. medical conditions for which 300ml of intravenous fluid is considered dangerous (i.e., decompensated heart failure or renal failure with fluid overload). 11. inability to consent and/or comply with study requirements, in the opinion of the investigator. 12. currently participating or planning to participate in any interventional study for the treatment of covid-19 or sars-cov-2 infection until day 60.

1. if female, pregnant, breastfeeding, or planning a pregnancy during the study. 2. severe or critical covid-19: 1. severe covid-19: respiratory frequency \>30 breaths per minute, spo2 \<94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) \<300 mmhg, or lung infiltrates \>50%. 2. critical covid-19: respiratory failure, septic shock, and/or multiple organ dysfunction. 3. current hospital admission for any cause. 4. history of previous confirmed sars-cov-2 infection. 5. history of significantly abnormal liver function (child pugh c). 6. history of chronic kidney disease (ckd) ≥ stage 4, or need of dialysis treatment. 7. any pre-existing condition that increases risk of thrombosis. 8. history of allergic reactions to blood or plasma products or methylene blue. 9. known iga deficiency with anti-iga antibodies. 10. medical conditions for which 300ml of intravenous fluid is considered dangerous (i.e., decompensated heart failure or renal failure with fluid overload). 11. inability to consent and/or comply with study requirements, in the opinion of the investigator. 12. currently participating or planning to participate in any interventional study for the treatment of covid-19 or sars-cov-2 infection until day 60.

if female, pregnant, breastfeeding, or planning a pregnancy during the study. severe or critical covid-19: severe covid-19: respiratory frequency >30 breaths per minute, spo2 <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) <300 mmhg, or lung infiltrates >50%. critical covid-19: respiratory failure, septic shock, and/or multiple organ dysfunction. current hospital admission for any cause. history of previous confirmed sars-cov-2 infection. history of significantly abnormal liver function (child pugh c). history of chronic kidney disease (ckd) ≥ stage 4, or need of dialysis treatment. any pre-existing condition that increases risk of thrombosis. history of allergic reactions to blood or plasma products or methylene blue. known iga deficiency with anti-iga antibodies. medical conditions for which 300ml of intravenous fluid is considered dangerous (i.e., decompensated heart failure or renal failure with fluid overload). inability to consent and/or comply with study requirements, in the opinion of the investigator. currently participating or planning to participate in any interventional study for the treatment of covid-19 or sars-cov-2 infection until day 60.

if female, pregnant, breastfeeding, or planning a pregnancy during the study. severe or critical covid-19: severe covid-19: respiratory frequency >30 breaths per minute, spo2 <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) <300 mmhg, or lung infiltrates >50%. critical covid-19: respiratory failure, septic shock, and/or multiple organ dysfunction. current hospital admission for any cause. history of previous confirmed sars-cov-2 infection. history of significantly abnormal liver function (child pugh c). history of chronic kidney disease (ckd) ≥ stage 4, or need of dialysis treatment. any pre-existing condition that increases risk of thrombosis. history of allergic reactions to blood or plasma products or methylene blue. known iga deficiency with anti-iga antibodies. medical conditions for which 300ml of intravenous fluid is considered dangerous (i.e., decompensated heart failure or renal failure with fluid overload). inability to consent and/or comply with study requirements, in the opinion of the investigator. currently participating or planning to participate in any interventional study for the treatment of covid-19 or sars-cov-2 infection until day 60.

1. if female, pregnant, breastfeeding, or planning a pregnancy during the study. 2. severe or critical covid-19: 1. severe covid-19: respiratory frequency >30 breaths per minute, spo2 <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) <300 mmhg, or lung infiltrates >50%. 2. critical covid-19: respiratory failure, septic shock, and/or multiple organ dysfunction. 3. current hospital admission for any cause. 4. history of previous confirmed sars-cov-2 infection. 5. history of significantly abnormal liver function (child pugh c). 6. history of chronic kidney disease (ckd) ≥ stage 4, or need of dialysis treatment. 7. any pre-existing condition that increases risk of thrombosis. 8. history of allergic reactions to blood or plasma products or methylene blue. 9. known iga deficiency with anti-iga antibodies. 10. medical conditions for which 300ml of intravenous fluid is considered dangerous (i.e., decompensated heart failure or renal failure with fluid overload). 11. inability to consent and/or comply with study requirements, in the opinion of the investigator. 12. currently participating or planning to participate in any interventional study for the treatment of covid-19 or sars-cov-2 infection until day 60.

1. if female, pregnant, breastfeeding, or planning a pregnancy during the study. 2. severe or critical covid-19: 1. severe covid-19: respiratory frequency >30 breaths per minute, spo2 <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) <300 mmhg, or lung infiltrates >50%. 2. critical covid-19: respiratory failure, septic shock, and/or multiple organ dysfunction. 3. current hospital admission for any cause. 4. history of previous confirmed sars-cov-2 infection. 5. history of significantly abnormal liver function (child pugh c). 6. history of chronic kidney disease (ckd) ≥ stage 4, or need of dialysis treatment. 7. any pre-existing condition that increases risk of thrombosis. 8. history of allergic reactions to blood or plasma products or methylene blue. 9. known iga deficiency with anti-iga antibodies. 10. medical conditions for which 300ml of intravenous fluid is considered dangerous (i.e., decompensated heart failure or renal failure with fluid overload). 11. inability to consent and/or comply with study requirements, in the opinion of the investigator. 12. currently participating or planning to participate in any interventional study for the treatment of covid-19 or sars-cov-2 infection until day 60.

1. if female, pregnant, breastfeeding, or planning a pregnancy during the study. 2. severe or critical covid-19: 1. severe covid-19: respiratory frequency >30 breaths per minute, spo2 <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) <300 mmhg, or lung infiltrates >50%. 2. critical covid-19: respiratory failure, septic shock, and/or multiple organ dysfunction. 3. current hospital admission for any cause. 4. history of previous confirmed sars-cov-2 infection. 5. history of significantly abnormal liver function (child pugh c). 6. history of chronic kidney disease (ckd) ≥ stage 4, or need of dialysis treatment. 7. any pre-existing condition that increases risk of thrombosis. 8. history of allergic reactions to blood or plasma products or methylene blue. 9. known iga deficiency with anti-iga antibodies. 10. medical conditions for which 250 ml of intravenous fluid is considered dangerous (i.e., decompensated heart failure or renal failure with fluid overload). 11. inability to consent and/or comply with study requirements, in the opinion of the investigator. 12. currently participating or planning to participate in any interventional study for the treatment of covid-19 or sars-cov-2 infection until day 60.

1. if female, pregnant, breastfeeding, or planning a pregnancy during the study. 2. severe or critical covid-19: 1. severe covid-19: respiratory frequency >30 breaths per minute, spo2 <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) <300 mmhg, or lung infiltrates >50%. 2. critical covid-19: respiratory failure, septic shock, and/or multiple organ dysfunction. 3. current hospital admission for any cause. 4. history of previous confirmed sars-cov-2 infection. 5. history of significantly abnormal liver function (child pugh c). 6. history of chronic kidney disease (ckd) ≥ stage 4, or need of dialysis treatment. 7. any pre-existing condition that increases risk of thrombosis. 8. history of allergic reactions to blood or plasma products or methylene blue. 9. known iga deficiency with anti-iga antibodies. 10. medical conditions for which 250 ml of intravenous fluid is considered dangerous (i.e., decompensated heart failure or renal failure with fluid overload). 11. inability to consent and/or comply with study requirements, in the opinion of the investigator. 12. currently participating or planning to participate in any interventional study for the treatment of covid-19 or sars-cov-2 infection until day 60.